Application note: Workflow for high-throughput glycoprofiling of rituximab
Posted: 1 November 2022 | Merck | No comments yet
Protocol for purification, reduction, and SEC-MS glycoform analysis of a therapeutic monoclonal antibody (mAb)
Discover in this application note the complete SEC-MS workflow, developed to enable rapid glycoprofiling of monoclonal antibodies (mAbs) in cell culture supernatants. It includes:
- Antibody (mAb) purification using immobilised protein A
- Antibody reduction procedure
- Mass spectrometer calibration
- System suitability test utilising a recombinant human monoclonal antibody reference
- Size exclusion chromatography – mass spectrometry (SEC-MS) method for sample separation and analysis.
Related content from this organisation
- MSD set to acquire novel antibody for B-cell malignancies
- Novel immunotherapy combination approved for endometrial cancer
- Innovating small molecule injectables: market forecast to 2033
- Ophthalmology acquisition to advance tri-specific antibody
- Antibody-immunotherapy treatment shows benefit in serious endometrial cancer
Related topics
Biopharmaceuticals, Formulation, Manufacturing, QA/QC, Research & Development (R&D)